<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Insights Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Insights Imaging</journal-id><journal-title-group><journal-title>Insights into Imaging</journal-title></journal-title-group><issn pub-type="epub">1869-4101</issn><publisher><publisher-name>Springer Vienna</publisher-name><publisher-loc>Vienna</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40188300</article-id><article-id pub-id-type="pmc">PMC11972232</article-id><article-id pub-id-type="publisher-id">1960</article-id><article-id pub-id-type="doi">10.1186/s13244-025-01960-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Quality of prostate MRI in early diagnosis&#x02014;a national survey and reading evaluation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3200-608X</contrib-id><name><surname>Thijssen</surname><given-names>Linda C. P.</given-names></name><address><email>linda.thijssen@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Twilt</surname><given-names>Jasper J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Barrett</surname><given-names>Tristan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Giganti</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Schoots</surname><given-names>Ivo G.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Engels</surname><given-names>Rianne R. M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Broeders</surname><given-names>Mireille J. M.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Barentsz</surname><given-names>Jelle O.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>de Rooij</surname><given-names>Maarten</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05wg1m734</institution-id><institution-id institution-id-type="GRID">grid.10417.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 9382</institution-id><institution>Department of Medical Imaging, </institution><institution>Radboud University Medical Center, </institution></institution-wrap>Nijmegen, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013meh722</institution-id><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution>Department of Radiology, </institution><institution>Addenbrooke&#x02019;s Hospital and University of Cambridge, </institution></institution-wrap>Cambridge, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wrevg56</institution-id><institution-id institution-id-type="GRID">grid.439749.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0612 2754</institution-id><institution>Department of Radiology, </institution><institution>University College London Hospital NHS Foundation Trust, </institution></institution-wrap>London, UK </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 1201</institution-id><institution>Division of Surgery and Interventional Science, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/018906e22</institution-id><institution-id institution-id-type="GRID">grid.5645.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0459 992X</institution-id><institution>Department of Radiology &#x00026; Nuclear Medicine, </institution><institution>Erasmus University Medical Centre, </institution></institution-wrap>Rotterdam, The Netherlands </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03xqtf034</institution-id><institution-id institution-id-type="GRID">grid.430814.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0674 1393</institution-id><institution>Department of Radiology, </institution><institution>Netherlands Cancer Institute, </institution></institution-wrap>Amsterdam, The Netherlands </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05wg1m734</institution-id><institution-id institution-id-type="GRID">grid.10417.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 9382</institution-id><institution>Department for Health Evidence, </institution><institution>Radboud University Medical Center, </institution></institution-wrap>Nijmegen, The Netherlands </aff><aff id="Aff8"><label>8</label>Andros Clinics, Arnhem, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><elocation-id>82</elocation-id><history><date date-type="received"><day>18</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>25</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objectives</title><p id="Par1">The reliability of image-based recommendations in the prostate cancer pathway is partially dependent on prostate MRI image quality. We evaluated the current compliance with PI-RADSv2.1 technical recommendations and the prostate MRI image quality in the Netherlands. To aid image quality improvement, we identified factors that possibly influence image quality.</p></sec><sec><title>Materials and methods</title><p id="Par2">A survey was sent to 68 Dutch medical centres to acquire information on prostate MRI acquisition. The responding medical centres were requested to provide anonymised prostate MRI examinations of biopsy-naive men suspected of prostate cancer. The images were evaluated for quality by three expert prostate radiologists. The compliance with PI-RADSv2.1 technical recommendations and the PI-QUALv2 score was calculated. Relationships between hardware, education of personnel, technical parameters, and/or patient preparation and both compliance and image quality were analysed using Pearson correlation, Mann&#x02013;Whitney <italic>U</italic>-test, or Student's <italic>t</italic>-test where appropriate.</p></sec><sec><title>Results</title><p id="Par3">Forty-four medical centres submitted their compliance with PI-RADSv2.1 technical recommendations, and 26 medical centres completed the full survey. Thirteen hospitals provided 252 usable images. The mean compliance with technical recommendations was 79%. Inadequate PI-QUALv2 scores were given in 30.9% and 50.6% of the mp-MRI and bp-MRI examinations, respectively. Multiple factors with a possible relationship with image quality were identified.</p></sec><sec><title>Conclusion</title><p id="Par4">In the Netherlands, the average compliance with PI-RADSv2.1 technical recommendations is high. Prostate MRI image quality was inadequate in 30&#x02013;50% of the provided examinations. Many factors not covered in the PI-RADSv2.1 technical recommendations can influence image quality. Improvement of prostate MRI image quality is needed.</p></sec><sec><title>Critical relevance statement</title><p id="Par5">It is essential to improve the image quality of prostate MRIs, which can be achieved by addressing factors not covered in the PI-RADSv2.1 technical recommendations.</p></sec><sec><title>Key Points</title><p id="Par6">
<list list-type="bullet"><list-item><p id="Par7">Prostate MRI image quality influences the diagnostic accuracy of image-based decisions.</p></list-item><list-item><p id="Par8">Thirty to fifty percent of Dutch prostate MRI examinations were of inadequate image quality.</p></list-item><list-item><p id="Par9">We identified multiple factors with possible influence on image quality.</p></list-item></list>
</p></sec><sec><title>Graphical Abstract</title><p id="Par10">
<graphic position="anchor" xlink:href="13244_2025_1960_Figa_HTML" id="d33e301"/>
</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Prostatic neoplasms</kwd><kwd>Magnetic resonance imaging</kwd><kwd>Image quality</kwd><kwd>Netherlands</kwd><kwd>PI-QUALv2</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; European Society of Radiology (ESR) 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par22">Since 2012, prostate cancer (PCa) has been listed as the second most diagnosed cancer and the fifth cause of cancer-related death in men worldwide [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. With an ageing population, PCa is likely to remain an important health care problem. The PROMIS, PRECISION, 4M, and MR PROPER studies have shown that the MRI pathway for PCa decreases overdiagnosis and overtreatment of indolent PCa, with equal detection of clinically significant PCa while reducing the number of biopsies [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Due to this benefit, international guidelines were changed and now recommend MRI prior to biopsy [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], which accelerated the uptake of MRI in the PCa pathway [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par23">However, the variable diagnostic performance in daily practice has raised concerns about the diagnostic accuracy of prostate MRI [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. The performance of MRI for the detection of PCa is strongly dependent on the radiologist&#x02019;s experience [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>] and image quality [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Image quality is, in turn, influenced by patient-related factors [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], hardware employed [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>], and technical parameters [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. The prostate imaging reporting and data system (PI-RADS) version 2.1 recommends minimal technical requirements [<xref ref-type="bibr" rid="CR23">23</xref>]. The compliance of European and American institutions with these recommendations is highly variable [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>]. Although several groups have investigated the correlation between PI-RADS technical recommendation compliance and image quality [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], these recommendations are aimed at acquiring acceptable MRI examinations, rather than prescribing technical parameters for optimal image quality.</p><p id="Par24">We used a survey to investigate how prostate MR imaging is performed, and a reader study to determine the current prostate MRI image quality in the Netherlands. Additionally, we evaluated the compliance with PI-RADSv2.1 technical recommendations and explored associations between image quality and patient preparation, education of personnel, MRI hardware, and technical parameters.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par25">The institutional review board granted ethical approval and waived written informed consent for the retrospective use of anonymised images.</p><sec id="Sec3"><title>Study design</title><p id="Par26">Our observational retrospective study entails three consecutive parts;</p><p id="Par27">Part 1: an online survey to gain insight into the four key domains of prostate MRI acquisition in the Netherlands:<list list-type="alpha-lower"><list-item><p id="Par28">Hardware;</p></list-item><list-item><p id="Par29">Technical parameters;</p></list-item><list-item><p id="Par30">Patient preparation;</p></list-item><list-item><p id="Par31">Education of personnel.</p></list-item></list></p><p id="Par32">The survey answers were used to assess the compliance with the PI-RADSv2.1 technical recommendations and possible relationships between PI-RADSv2.1 compliance and hardware or education of personnel (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, in blue).</p><p id="Par33">Part 2: prostate MRI image quality was assessed in a subset of the responding centres to determine the current state of prostate MRI quality in the Netherlands (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, in yellow).</p><p id="Par34">Part 3: The results of both parts were combined to explore associations between image quality and survey answers (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, in green).<fig id="Fig1"><label>Fig. 1</label><caption><p>Infographic on study organisation. Blue: part of the study based on a survey. Yellow: part of the study based on the reader study. Green: part of the study based on both survey and reader study</p></caption><graphic xlink:href="13244_2025_1960_Fig1_HTML" id="d33e511"/></fig></p><p id="Par35">For the first part, an online survey was developed using LimeSurvey, and tested by a multidisciplinary team from a tertiary prostate MRI centre consisting of prostate radiologists, dedicated radiographers, clinical researchers, and an epidemiologist. The online questionnaire surveyed the above-mentioned four key domains that can influence prostate MRI image quality. See Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and supplementary information for all parameters included in the questionnaire (Supplementary Tables&#x000a0;<xref rid="MOESM1" ref-type="media">4</xref>&#x02013;<xref rid="MOESM1" ref-type="media">9</xref>). In 2020, an invitation containing a unique link to the voluntary online survey was sent by e-mail to the Radiology departments of all hospitals in the Netherlands, excluding a specialist paediatric hospital (<italic>n</italic>&#x02009;=&#x02009;68). A reminder was sent after two weeks to all hospitals that did not respond or did not fully complete the survey. In case of non-representative or unclear answers, the respondents were contacted by email and asked to verify their answers.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Compliance per PI-RADS technical recommendation</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>PI-RADS v2.1 technical recommendation</th><th>compliance, (<italic>n</italic>)</th></tr></thead><tbody><tr><td rowspan="3">General</td><td>T1 with the FOV including pelvic lymph nodes to the aortic bifurcation</td><td>57% (25/44)</td></tr><tr><td>Multiparametric acquisition (T2W, DWI, and DCE)</td><td>43% (19/44)</td></tr><tr><td>Imaging plane angle, location and slice thickness for all sequences (T2W and DWI&#x000a0;for all acquisitions, and&#x000a0;additionally DCE&#x000a0;only for multiparametric acquisitions) are identical</td><td>26% (5/19) (mp), 72% (18/25) (bp), 52% (23/44) (all)</td></tr><tr><td rowspan="6">Axial T2W</td><td>Additional sagittal and/or coronal</td><td>98% (43/44)</td></tr><tr><td>Slice thickness&#x02009;&#x02264;&#x02009;3&#x02009;mm</td><td>84% (37/44)</td></tr><tr><td>Interslice gap absent</td><td>59% (26/44)</td></tr><tr><td>Field of view 12&#x02013;20&#x02009;cm</td><td>75% (33/44)</td></tr><tr><td>In-plane resolution (phase)&#x02009;&#x02264;&#x02009;0.7&#x02009;mm</td><td>82% (36/44)</td></tr><tr><td>In-plane resolution (frequency)&#x02009;&#x02264;&#x02009;0.4&#x02009;mm</td><td>6.8% (3/44)</td></tr><tr><td rowspan="9">DWI</td><td>Slice thickness&#x02009;&#x02264;&#x02009;4&#x02009;mm</td><td>95% (42/44)</td></tr><tr><td>Interslice gap absent</td><td>64% (28/44)</td></tr><tr><td>Field of view 16&#x02013;22&#x02009;cm</td><td>59% (26/44)</td></tr><tr><td>In-plane resolution (phase)&#x02009;&#x02264;&#x02009;2.5&#x02009;mm</td><td>82% (36/44)</td></tr><tr><td>In-plane resolution (frequency)&#x02009;&#x02264;&#x02009;2.5&#x02009;mm</td><td>82% (36/44)</td></tr><tr><td>Angulation similar to T2</td><td>100% (44/44)</td></tr><tr><td>ADC map high <italic>b</italic>-value 800&#x02013;1000</td><td>91% (40/44)</td></tr><tr><td>ADC map low <italic>b</italic>-value 0&#x02013;100&#x02009;s/mm<sup>2</sup></td><td>98% (43/44)</td></tr><tr><td>Highest <italic>b</italic>-value&#x02009;&#x02265;&#x02009;1400&#x02009;s/mm<sup>2</sup></td><td>80% (35/44)</td></tr><tr><td rowspan="11">DCE</td><td>Slice thickness&#x02009;&#x02264;&#x02009;3&#x02009;mm</td><td>53% (10/19)</td></tr><tr><td>Interslice gap absent</td><td>68% (13/19)</td></tr><tr><td>In-plane resolution (phase)&#x02009;&#x02264;&#x02009;2&#x02009;mm</td><td>95% (18/19)</td></tr><tr><td>In-plane resolution (frequency)&#x02009;&#x02264;&#x02009;2&#x02009;mm</td><td>95% (18/19)</td></tr><tr><td>Angulation similar to T2</td><td>100% (19/19)</td></tr><tr><td>TR&#x02009;&#x0003c;&#x02009;100&#x02009;ms</td><td>100% (19/19)</td></tr><tr><td>TE&#x02009;&#x0003c;&#x02009;5&#x02009;ms</td><td>100% (19/19)</td></tr><tr><td>Temporal resolution&#x02009;&#x02264;&#x02009;15&#x02009;s</td><td>100% (19/19)</td></tr><tr><td>Total observation time&#x02009;&#x02265;&#x02009;2&#x02009;min</td><td>100% (19/19)</td></tr><tr><td>Dose of 0.1&#x02009;mmol/kg GBCA or equivalent</td><td>47% (9/19)</td></tr><tr><td>Injection rate 2&#x02013;3&#x02009;mL/s</td><td>95% (18/19)</td></tr></tbody></table><table-wrap-foot><p><italic>ADC</italic> apparent diffusion coefficient, <italic>DCE</italic> dynamic contrast-enhanced, <italic>DWI</italic> diffusion weighted imaging, <italic>TE</italic> echo time, <italic>TR</italic> repetition time, <italic>T2W</italic> T2-weighted</p></table-wrap-foot></table-wrap></p><p id="Par36">For the second part, all hospitals that completed the survey were requested to share the first 20 consecutive prostate MRI examinations acquired that year for image quality assessment. The provided examinations were scored for image quality by 3&#x02013;5 expert prostate radiologists (&#x0003e;&#x02009;1000 cases read, &#x0003e;&#x02009;200 cases/year) [<xref ref-type="bibr" rid="CR30">30</xref>] from four different international institutions (T.B., I.G.S., J.O.B., F.G., and M.d.R.). The radiologists assessed each available sequence for image quality by using a development version of the Prostate imaging quality v2 scoring system (PI-QUALv2), using quality criteria (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) slightly different from the final version criteria [<xref ref-type="bibr" rid="CR31">31</xref>].<table-wrap id="Tab2"><label>Table 2</label><caption><p>Image quality criteria per sequence</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="4">T2W</td><td>Axial: adequate signal-to-noise ratio in the periprostatic fat</td></tr><tr><td>Axial: ability to clearly delineate relevant prostate structures</td></tr><tr><td>Axial: absence of (severe) artefacts in prostate region</td></tr><tr><td>Sagittal OR coronal: ability to clearly delineate relevant prostate structures</td></tr><tr><td rowspan="4">DWI</td><td>Adequate signal-to-noise ratio on high <italic>b</italic>-value images (b1400 or higher)</td></tr><tr><td>Adequate range of contrast to identify TZ from PZ on ADC map</td></tr><tr><td>Absence of (severe) artefacts in the prostate region</td></tr><tr><td>DWI in plane matching with T2W imaging (&#x0003c;&#x02009;5&#x02009;mm at the posterior prostate)</td></tr><tr><td rowspan="2">DCE</td><td>Image quality that allows the assessment of enhancement of the prostatic structures</td></tr><tr><td>Ability to identify anatomical structures (for instance, pudendal arteries)</td></tr></tbody></table><table-wrap-foot><p><italic>ADC</italic> apparent diffusion coefficient, <italic>DCE</italic> dynamic contrast-enhanced MRI, <italic>DWI</italic> diffusion weighted imaging, <italic>PZ</italic> peripheral zone, <italic>T2W</italic> T2-weighted, <italic>TZ</italic> transition zone</p></table-wrap-foot></table-wrap></p><p id="Par37">For the final part, relationships between the quality scores and the survey answers were analysed as described below.</p></sec><sec id="Sec4"><title>Statistical analysis</title><p id="Par38">Data was analysed using IBM SPSS Statistics (version 27). For each hospital, the mean quality score for each individual criterion was derived by dividing the sum of the scores assigned by the number of readers who performed the quality assessment for said criterion. Subsequently, the total quality score and total score per sequence were calculated for each centre. Additionally, the PI-QUALv2 score (inadequate/acceptable/optimal) that each reader assigned to each case was calculated. Interrater agreement for image quality assessment was evaluated using the intraclass correlation coefficient (ICC) based on a mean-rating (<italic>k</italic>&#x02009;=&#x02009;3&#x02013;5), absolute-agreement, 2-way random-effects model. The reliability of the assessment was considered poor if the ICC was &#x0003c;&#x02009;0.4, moderate between 0.4 and 0.59, good between 0.6 and 0.75, with an ICC&#x02009;&#x0003e;&#x02009;0.75 considered excellent. Pearson&#x02019;s correlation coefficient was used to analyse the correlation between continuous variables. The correlation was considered weak for a Pearson correlation coefficient (<italic>r</italic>) between 0.1 and 0.3, medium between 0.3 and 0.5, and strong between 0.5 and 1.0. Hospitals were divided into groups per feature for analysis of binary variables. To investigate differences in mean image quality and/or compliance between these groups, Mann&#x02013;Whitney <italic>U</italic>-test was used for small sample sizes where normality assumption could not be met, otherwise, Student&#x02019;s <italic>t</italic>-test was used. As this extensive analysis was performed to explore possible influencers of image quality and not to prove a causal relationship, no correction for multiple testing was done.</p></sec></sec><sec id="Sec5" sec-type="results"><title>Results</title><sec id="Sec6"><title>Part 1: survey</title><sec id="Sec7"><title>Response</title><p id="Par39">Fifty-eight of 68 hospitals (85%) responded, 48 of which (82.8%) performed prostate MRI for the detection of PCa. Forty-four out of 48 (92%) submitted their compliance with PI-RADSv2.1 technical recommendations, and 26/48 (54.2%) centres completed the full survey (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> and Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, &#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, and&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Out of these 26 centres, thirteen provided examinations, 6 of which (46%) were multiparametric (mp-)MRI, and 7 (54%) biparametric (bp-)MRI acquisitions. Eight examinations were excluded because of corrupted files or prior prostatectomy, resulting in 140&#x02009;bp and 112&#x02009;mp examinations (252 examinations total) for image quality assessment with PI-QUALv2.<fig id="Fig2"><label>Fig. 2</label><caption><p>Survey response</p></caption><graphic xlink:href="13244_2025_1960_Fig2_HTML" id="d33e860"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>Features showing possible association with image quality according to <italic>t</italic>-test</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Feature</th><th>Quality aspect</th><th>groups</th><th colspan="2">Mean quality (std)</th><th><italic>p</italic>-value</th><th>Degrees of freedom</th><th><italic>t</italic>-value</th></tr></thead><tbody><tr><td colspan="8">Hardware used</td></tr><tr><td rowspan="6">&#x02003;Field strength</td><td rowspan="2">bp quality</td><td>1.5&#x02009;T</td><td>5.32/8</td><td>(0.56)</td><td rowspan="2">0.016</td><td rowspan="2">11</td><td rowspan="2">&#x02212;2.85</td></tr><tr><td>3&#x02009;T</td><td>6.23/8</td><td>(0.59)</td></tr><tr><td rowspan="2">T2W quality</td><td>1.5&#x02009;T</td><td>2.80/4</td><td>(0.39)</td><td rowspan="2">0.029</td><td rowspan="2">11</td><td rowspan="2">&#x02212;2.52</td></tr><tr><td>3&#x02009;T</td><td>3.30/4</td><td>(0.33)</td></tr><tr><td rowspan="2">DWI quality</td><td>1.5&#x02009;T</td><td>2.53/4</td><td>(0.32)</td><td rowspan="2">0.039</td><td rowspan="2">11</td><td rowspan="2">&#x02212;2.34</td></tr><tr><td>3&#x02009;T</td><td>2.93/4</td><td>(0.30)</td></tr><tr><td rowspan="2">&#x02003;Ventral coil type<sup>a</sup></td><td rowspan="2">DWI: Adequate range of contrast to identify TZ from PZ on ADC map</td><td>Pelvic</td><td>0.69/1</td><td>(0.15)</td><td rowspan="2">0.028</td><td rowspan="2">10.88</td><td rowspan="2">&#x02212;2.54</td></tr><tr><td>Body</td><td>0.84/1</td><td>(0.06)</td></tr><tr><td colspan="8">Technical settings</td></tr><tr><td rowspan="4">&#x02003;Phase encoding direction sagittal T2W</td><td rowspan="2">T2W quality</td><td>CC</td><td>3.32/4</td><td>(0.32)</td><td rowspan="2">0.038</td><td rowspan="2">10</td><td rowspan="2">2.39</td></tr><tr><td>AP</td><td>2.83/4</td><td>(0.38)</td></tr><tr><td rowspan="2">T2W sagittal OR coronal: ability to clearly delineate relevant prostate structures</td><td>CC</td><td>0.87/1</td><td>(0.07)</td><td rowspan="2">0.019</td><td rowspan="2">10</td><td rowspan="2">2.80</td></tr><tr><td>AP</td><td>0.72/1</td><td>(0.11)</td></tr><tr><td colspan="8">Patient preparation</td></tr><tr><td rowspan="2">&#x02003;Antispasmodic use</td><td rowspan="2">T2W axial: adequate signal-to-noise ratio in the periprostatic fat</td><td>No</td><td>0.53/1</td><td>(0.12)</td><td rowspan="2">&#x0003c;&#x02009;0.001</td><td rowspan="2">11</td><td rowspan="2">&#x02212;4.74</td></tr><tr><td>Yes</td><td>0.82/1</td><td>(0.10)</td></tr><tr><td rowspan="6">&#x02003;Refrain from ejaculation</td><td rowspan="2">bp quality</td><td>No</td><td>5.18/8</td><td>(0.59)</td><td rowspan="2">0.020</td><td rowspan="2">11</td><td rowspan="2">&#x02212;2.72</td></tr><tr><td>Yes</td><td>6.09/8</td><td>(0.58)</td></tr><tr><td rowspan="2">T2W quality</td><td>No</td><td>2.72/4</td><td>(0.41)</td><td rowspan="2">0.033</td><td rowspan="2">11</td><td rowspan="2">&#x02212;2.43</td></tr><tr><td>Yes</td><td>3.23/4</td><td>(0.34)</td></tr><tr><td rowspan="2">DWI quality</td><td>No</td><td>2.47/4</td><td>(0.31)</td><td rowspan="2">0.048</td><td rowspan="2">11</td><td rowspan="2">&#x02212;2.23</td></tr><tr><td>Yes</td><td>2.86/4</td><td>(0.32)</td></tr><tr><td rowspan="4">&#x02003;Use of laxative<sup>b</sup></td><td rowspan="2">T2W axial: adequate signal-to-noise ratio in the periprostatic fat</td><td>No</td><td>0.72/1</td><td>(0.15)</td><td rowspan="2">0.038</td><td rowspan="2">10</td><td rowspan="2">2.39</td></tr><tr><td>Yes</td><td>0.35/1</td><td>(&#x02013;)</td></tr><tr><td rowspan="2">T2W sagittal OR coronal: ability to clearly delineate relevant prostate structures</td><td>No</td><td>0.79/1</td><td>(0.09)</td><td rowspan="2">0.012</td><td rowspan="2">10</td><td rowspan="2">3.08</td></tr><tr><td>Yes</td><td>0.52/1</td><td>(&#x02013;)</td></tr><tr><td rowspan="10">&#x02003;Use of rectal catheter<sup>b</sup></td><td rowspan="2">mp quality</td><td>No</td><td>6.29/10</td><td>(0.39)</td><td rowspan="2">0.016</td><td rowspan="2">3</td><td rowspan="2">&#x02212;4.92</td></tr><tr><td>Yes</td><td>8.42/10</td><td>(&#x02013;)</td></tr><tr><td rowspan="2">bp quality</td><td>No</td><td>5.52/8</td><td>(0.51)</td><td rowspan="2">0.014</td><td rowspan="2">10</td><td rowspan="2">&#x02212;2.98</td></tr><tr><td>Yes</td><td>7.12/8</td><td>(&#x02013;)</td></tr><tr><td rowspan="2">T2W quality</td><td>No</td><td>2.91/4</td><td>(0.35)</td><td rowspan="2">0.031</td><td rowspan="2">10</td><td rowspan="2">&#x02212;2.51</td></tr><tr><td>yes</td><td>3.82/4</td><td>(&#x02013;)</td></tr><tr><td rowspan="2">DWI quality</td><td>No</td><td>2.61/4</td><td>(0.28)</td><td rowspan="2">0.041</td><td rowspan="2">10</td><td rowspan="2">&#x02212;2.35</td></tr><tr><td>Yes</td><td>3.29/4</td><td>(&#x02212;)</td></tr><tr><td rowspan="2">DWI: Adequate signal-to-noise ratio on high <italic>b</italic>-value images (b1400 or higher)</td><td>No</td><td>0.40/1</td><td>(0.13)</td><td rowspan="2">0.013</td><td rowspan="2">10</td><td rowspan="2">&#x02212;3.00</td></tr><tr><td>Yes</td><td>0.80/1</td><td>(&#x02212;)</td></tr><tr><td colspan="8">Education of personnel</td></tr><tr><td rowspan="6">&#x02003;Education radiologist</td><td rowspan="2">bp quality</td><td>No</td><td>4.47/8</td><td>(0.16)</td><td rowspan="2">0.031</td><td rowspan="2">11</td><td rowspan="2">&#x02212;2.47</td></tr><tr><td>Yes</td><td>5.92/8</td><td>(0.63)</td></tr><tr><td rowspan="2">T2W quality</td><td>No</td><td>2.41/4</td><td>(0.11)</td><td rowspan="2">0.020</td><td rowspan="2">11</td><td rowspan="2">&#x02212;2.72</td></tr><tr><td>Yes</td><td>3.14/4</td><td>(0.37)</td></tr><tr><td rowspan="2">T2W axial: adequate signal-to-noise ratio in the periprostatic fat</td><td>No</td><td>0.42/1</td><td>(0.09)</td><td rowspan="2">0.006</td><td rowspan="2">11</td><td rowspan="2">&#x02212;3.37</td></tr><tr><td>Yes</td><td>0.76/1</td><td>(0.14)</td></tr></tbody></table><table-wrap-foot><p>Only correlations with a <italic>p</italic>-value&#x02009;&#x0003c;&#x02009;0.05 are included in this table. See supplementary information for a full table</p><p><italic>ADC</italic> apparent diffusion coefficient, <italic>AP</italic> anterior-posterior, <italic>bp</italic> biparametric, <italic>CC</italic> craniocaudal, <italic>DWI</italic> diffusion weighted imaging, <italic>mp</italic> multiparametric, <italic>PZ</italic> peripheral zone, <italic>T2W</italic> T2-weighted imaging, <italic>TZ</italic> transition zone</p><p><sup>a</sup> Levene&#x02019;s test for equality of variances was found to be violated for this analysis (<italic>F</italic>(1, 10)&#x02009;=&#x02009;0.6.41, <italic>p</italic>&#x02009;=&#x02009;0.028). Owing to this violated assumption, a <italic>t</italic>-statistic not assuming homogeneity of variance was computed</p><p><sup>b</sup> Feature is used by a single hospital</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>Features showing Pearson correlation with image quality</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Feature</th><th>Quality aspect</th><th>Degrees of freedom</th><th>Correlation coefficient (<italic>r</italic>)</th><th><italic>p</italic>-value</th></tr></thead><tbody><tr><td colspan="5">Technical settings</td></tr><tr><td>&#x02003;Interslice gap T2W axial<sup>a</sup></td><td>T2W axial: adequate signal-to-noise ratio in the periprostatic fat</td><td>11</td><td>&#x02212;0.57</td><td>0.040</td></tr><tr><td rowspan="2">&#x02003;Resolution T2W axial&#x02014;frequency direction</td><td>Total T2W quality</td><td>11</td><td>&#x02212;0.64</td><td>0.019</td></tr><tr><td>T2W axial: ability to clearly delineate relevant prostate structures</td><td>11</td><td>&#x02212;0.69</td><td>0.009</td></tr><tr><td>&#x02003;Slice thickness T2W sagittal</td><td>T2W sagittal OR coronal: ability to clearly delineate relevant prostate structures</td><td>11</td><td>&#x02212;0.58</td><td>0.038</td></tr><tr><td>&#x02003;Field of view T2W sagittal phase direction</td><td>T2W sagittal OR coronal: ability to clearly delineate relevant prostate structures</td><td>11</td><td>0.65</td><td>0.016</td></tr><tr><td rowspan="2">Interslice gap DWI</td><td>Total DWI quality</td><td>11</td><td>0.67</td><td>0.013</td></tr><tr><td>DWI: adequate SNR on high <italic>b</italic>-value images</td><td>11</td><td>0.78</td><td>0.002</td></tr><tr><td>Highest <italic>b</italic>-value</td><td>DWI in plane matching with T2W</td><td>11</td><td>0.80</td><td>0.001</td></tr></tbody></table><table-wrap-foot><p>Only correlations with a <italic>p</italic>-value&#x02009;&#x0003c;&#x02009;0.5 are included in this table. See Supplementary Information for a full table <italic>T2W</italic> T2-weighted imaging</p><p><sup>a</sup> The negative correlation is caused by an extreme outlier</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8"><title>PI-RADSv2.1 technical recommendations</title><p id="Par40">The median compliance with PI-RADSv2.1 technical recommendations for the hospitals that completed the survey was 74% (interquartile range (IQR) 70&#x02013;79%), similar to the compliance of the subset of hospitals that provided prostate MRI examinations for image quality assessment (median 78%, (IQR 72&#x02013;83%). The median compliance per hospital for mp-MRI was 79% (IQR 76&#x02013;86%) and 72% (IQR 67&#x02013;78%) for bp-MRI.</p><p id="Par41">The T2W recommendations had a median compliance of 78% (IQR 46&#x02013;88%), with lower compliance for the absence of an interslice gap, and in particular, for resolution in the frequency direction. The average compliance for DWI recommendations was 86% (IQR 68&#x02013;97%), with a high compliance for slice thickness and apparent diffusion coefficient (ADC) map values and low compliance for the absence of an interslice gap and field of view. The mean compliance for dynamic contrast enhanced (DCE) recommendations was 95% (IQR 68&#x02013;100%), with low compliance for absence of an interslice gap, slice thickness, and gadolinium-based contrast agent dose. The general PI-RADSv2.1 recommendations had a mean compliance of 52%, with notably low compliance for identical plane angle, location and slice thickness for mp-MRI (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p></sec></sec><sec id="Sec9"><title>Part 2: image quality assessment</title><sec id="Sec10"><title>Interrater agreement and image quality</title><p id="Par42">Interrater agreement for image quality assessment was moderate to good (ICC 0.55&#x02013;0.62). The mean image quality was 3.0&#x02009;&#x000b1;&#x02009;0.9/4 (mean&#x02009;&#x000b1;&#x02009;std/number of criteria) for T2 weighted imaging (T2W) acquisitions, 2.8&#x02009;&#x000b1;&#x02009;0.8/4 (mean&#x02009;&#x000b1;&#x02009;std/number of criteria) for diffusion weighted imaging (DWI) acquisitions, and 1.1&#x02009;&#x000b1;&#x02009;0.5/2 (mean&#x02009;&#x000b1;&#x02009;std/number of criteria) for DCE acquisition. The mean total quality was 7.3&#x02009;&#x000b1;&#x02009;1.5/10 (mean&#x02009;&#x000b1;&#x02009;std/number of criteria) for mp-MRI acquisitions, and 5.8&#x02009;&#x000b1;&#x02009;1.5/8 (mean&#x02009;&#x000b1;&#x02009;std/number of criteria) for bp-MRI acquisitions. For the mp-MRI cases, an optimal PI-QUALv2 score was given in 20.2%, 48.9% scored acceptable, and 30.9% inadequate. The bp-cases scored optimal in 15.6%, acceptable in 33.8% and inadequate in 50.6%. Although PI-QUALv2 states mp-MRI quality must be evaluated with DCE images [<xref ref-type="bibr" rid="CR31">31</xref>], we did score the mp-cases as bp-cases to determine to what extent the lower percentage of inadequate cases for mp-MRI was due to the DCE sequences providing a &#x02018;safety net&#x02019;. When the mp-cases were scored as bp-cases, 30.0% of the cases scored optimal, 29.5% acceptable, and 40.5% scored inadequate for PI-QUALv2 image quality.</p></sec></sec><sec id="Sec11"><title>Part 3: survey results in four key domains and possible associations with image quality</title><sec id="Sec12"><title>Hardware</title><p id="Par43">Mp-MRI was performed by 43% of the hospitals (19/44, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The most common field strength was 3 Tesla (T) (60%, 29/48), while 40% of the respondents (19/48) used 1.5&#x02009;T. The mean age of the scanners was 5.3 years (range 0&#x02013;11). None of the centres used an endorectal coil.</p><p id="Par44">Possible associations were found between several image quality aspects and hardware. A 3&#x02009;T field strength had higher image quality scores than 1.5&#x02009;T for total bp-MRI quality, total T2W quality, and total DWI quality. The body coil had a higher score for &#x0201c;DWI: Adequate range of contrast to identify TZ from PZ on ADC map&#x0201d; than the pelvic coil. We found a possible medium Pearson correlation between scanner age and general recommendations compliance (<italic>r</italic>(40)&#x02009;=&#x02009;&#x02212;0.315, <italic>p</italic>&#x02009;=&#x02009;0.042) and DWI recommendations (<italic>r</italic>(40)&#x02009;=&#x02009;&#x02212;0.340, <italic>p</italic>&#x02009;=&#x02009;0.028), but no indication for an association between compliance and field strength.</p></sec><sec id="Sec13"><title>Technical parameters</title><p id="Par45">When the phase encoding direction for the sagittal T2W scan was craniocaudal instead of anterior-posterior, higher quality scores were given for &#x0201c;T2W sagittal or coronal: ability to clearly delineate relevant prostate structures&#x0201d; and total T2W quality (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The size of the T2W axial interslice gap had a strong negative correlation with the quality score for adequate SNR, while the resolution for these images had a strong negative correlation with the ability to delineate relevant structures and the total T2 quality. For sagittal T2W images, the slice thickness was strongly negatively correlated with the ability to delineate relevant prostate structures, while the FOV in phase direction was strongly positively correlated with this ability. The DWI interslice gap showed a strong positive correlation with the adequate SNR on high <italic>b</italic>-value images, and total DWI quality. The value of the highest <italic>b</italic>-value was strongly positively correlated with the quality score for DWI in-plane matching with T2W (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).</p></sec><sec id="Sec14"><title>Patient preparation</title><p id="Par46">The patient preparation methods most commonly employed were antispasmodic agents (64.6% always, 31/48; 10.4% on indication, 5/48), and refraining from ejaculation (38.3% always, 18/48). Other patient preparation methods (i.e. laxatives, enemas, rectal catheters and dietary prescriptions) were only used sporadically (&#x0003c;&#x02009;5%) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par47">The use of an antispasmodic agent, refraining from ejaculation prior to the scan, and the use of a rectal catheter seem to positively influence several image quality aspects. The use of a laxative possibly has a negative influence on two T2W image quality aspects (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec15"><title>Education of personnel</title><p id="Par48">The majority of radiologists in the studied centres followed a dedicated educational course on prostate MRI (80.9%, 38/47). In 13 of these 38 centres, both radiologists and radiographers completed a course on prostate MRI (27.7%, 13/47).</p><p id="Par49">There was no correlation between the compliance with PI-RADSv2.1 technical recommendations and the attendance of a prostate MRI course by a radiographer and/or radiologist. Hospitals with radiologists who participated in a course dedicated to prostate MRI scored higher on T2W SNR, total T2W quality, and total bp quality (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec></sec></sec><sec id="Sec16" sec-type="discussion"><title>Discussion</title><p id="Par50">We assessed how prostate MRI is performed in the Netherlands by conducting an online survey in Dutch hospitals and evaluated the image quality of prostate MRI images in a subset of the respondents. We analysed the collected data to identify factors that potentially influence image quality.</p><sec id="Sec17"><title>Compliance with PI-RADSv2.1 technical recommendations</title><p id="Par51">We found a high, but variable adherence to PI-RADSv2.1 technical recommendations by parameter and by hospital, similar to the adherence found by previous groups [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>], but higher than that reported by Coskun et al [<xref ref-type="bibr" rid="CR25">25</xref>]. Notably, there was low adherence of 6.8% to the recommendation &#x0201c;T2W in-plane resolution (frequency)&#x02009;&#x02264;&#x02009;0.4&#x02009;mm&#x0201d;. This may be due to the inverse relationship between resolution and SNR. Therefore, it may be challenging to adhere to this recommendation without loss of image quality or significantly increasing scan time to compensate for quality loss, particularly at 1.5&#x02009;T. Another explanation could be that centres did not update their protocols after the 2015 publication of PI-RADSv2 [<xref ref-type="bibr" rid="CR32">32</xref>], as a significantly higher percentage 84% (37/44) was adherent to the PI-RADSv1 [<xref ref-type="bibr" rid="CR33">33</xref>] recommendation of an in-plane resolution of 0.5&#x02013;0.7&#x02009;mm in frequency direction.</p></sec><sec id="Sec18"><title>Image quality</title><p id="Par52">The overall image quality in this study, according to PI-QUALv2, was inadequate in 50.6% of bp-MRI and 30.9% of mp-MRI examinations. The number of studies of inadequate quality is relatively high, and if prostate MRI is to remain the preferred first step in PCa detection in the Netherlands, the overall MRI image quality must improve. Several studies have shown that when modifying the scanner protocol according to centre-specific expert recommendations, significant improvements in image quality can be achieved [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Although PI-RADSv2 recommends mp-MRI, the necessity of the DCE sequence has been debated, at least for certain patient populations, such as in a screening setting. If the radiologist is experienced in reading prostate MRI [<xref ref-type="bibr" rid="CR36">36</xref>], and the T2W and DWI images are of adequate image quality [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], DCE does not seem to offer an advantage that justifies the increased costs, scan time or risks of adverse reactions [<xref ref-type="bibr" rid="CR39">39</xref>]. In our sample, the average T2W and DWI image quality of the hospitals that perform bp-MRI is lower than that of the hospitals that perform mp-MRI. It raises concerns that the hospitals that would potentially benefit the most from DCE imaging refrain from acquiring that sequence.</p></sec><sec id="Sec19"><title>Hardware</title><p id="Par53">The positive influence of higher field strength on image quality is explained by the higher SNR [<xref ref-type="bibr" rid="CR40">40</xref>] and has been reported previously [<xref ref-type="bibr" rid="CR41">41</xref>]. The possible influence of surface coil type on the range of contrast seems counterintuitive. The body coil demonstrated a higher score for this quality aspect compared to a pelvic coil, despite the pelvic coil being marketed as being superior for prostate imaging. This may be explained by differences in the number of channels employed, which we did not quantify in the study.</p></sec><sec id="Sec20"><title>Technical parameters</title><p id="Par54">The negative effect of an interslice gap on image quality for axial T2W images was unexpected, since an interslice gap reduces slice cross-talk. Further analysis of the data revealed this correlation was due to a single extreme outlier; the centre with the lowest quality score reported an interslice gap of 15&#x02009;mm. When this centre was excluded from the analysis, there was a very weak positive Pearson correlation between interslice gap and the axial T2W SNR (<italic>r</italic>(10)&#x02009;=&#x02009;0.161, <italic>p</italic>&#x02009;=&#x02009;0.617).</p><p id="Par55">Some technical parameters that are mentioned in the PI-RADSv2.1 technical recommendations (i.e. absence of interslice gap and small FOV) seem to have a negative influence on quality when the parameters are (nearly) compliant with the recommended value. This shows that the PI-RADSv2.1 technical recommendations are meant to achieve adequate coverage and detailed images of the prostate, not to optimise image quality.</p></sec><sec id="Sec21"><title>Patient preparation</title><p id="Par56">The use of an antispasmodic agent to reduce image degradation due to bowel movement had a positive influence on T2W adequate SNR ratio in the periprostatic fat, consistent with prior studies [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. The use of a rectal catheter to evacuate gas from the rectum seemed to have a positive effect on DWI SNR. This reduction of air diminishes susceptibility artefacts and may also reduce peristalsis and thereby motion artefacts. However, it is important to note that a rectal catheter was used by only one hospital, and this correlation could be based on chance.</p></sec><sec id="Sec22"><title>Education of personnel</title><p id="Par57">In the hospitals where the radiologist followed a dedicated course on reporting prostate MRI, the images received a higher quality score. In the past, prostate imaging courses tended to focus mainly on prostate MRI interpretation, whereas the acquisition and image quality of prostate MRIs were covered to a lesser extent. After the introduction of a standardised scoring system for prostate image quality assessment, there has been an increasing awareness of prostate image quality. Both a UK consensus meeting [<xref ref-type="bibr" rid="CR44">44</xref>] and an expert panel [<xref ref-type="bibr" rid="CR45">45</xref>] recommend prostate MRI course participation in certification of prostate MRI radiologists. Prostate MRI educational courses should not solely focus on interpretation, but cover quality assessment as well, and include knowledge of potential causative factors to enable radiologist to adapt their protocols to obtain improved image quality. Recent studies have shown that courses on assessing prostate MRI quality improve the application of the PI-QUALv1 scoring system [<xref ref-type="bibr" rid="CR46">46</xref>&#x02013;<xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="Sec23"><title>Limitations</title><p id="Par58">Our study has some important limitations. As with any online survey, we relied on the accuracy and reliability of the respondents&#x02019; answers. Furthermore, it is possible that only the hospitals that were confident in their image quality chose to submit their images, leading to an overestimation of image quality. Although our survey covered multiple facets, image quality may have been influenced by additional features such as gradient strength, slew rate, number of activated coils, and the use of denoising filters. These unexplored variables could provide valuable insights in future research.</p><p id="Par59">Despite these limitations, our study provides important insights into the current state of prostate MRI image quality and highlights areas for potential improvement in imaging protocols and radiologist training.</p></sec></sec><sec id="Sec24" sec-type="conclusion"><title>Conclusion</title><p id="Par60">In the Netherlands, there is a good availability of hospitals that perform prostate MRI. On average, these hospitals have high compliance with PI-RADSv2.1 technical recommendations. However, 30&#x02013;50% of the studies of the 13 centres that submitted images were considered of inadequate image quality. Adherence to the PI-RADSv2.1 technical recommendations alone does not automatically result in acceptable or optimal image quality, as quality is influenced by other factors such as hardware, patient preparation, and technical settings, which are not specifically addressed in the PI-RADSv2.1 technical recommendations. Awareness of prostate image quality and continued education of personnel are key factors in delivering an adequate image-based diagnostic pathway of PCa.</p></sec><sec id="Sec25" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13244_2025_1960_MOESM1_ESM.pdf"><caption><p>ELECTRONIC SUPPLEMENTARY MATERIAL</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ADC</term><def><p id="Par11">Apparent diffusion coefficient</p></def></def-item><def-item><term>bp</term><def><p id="Par12">Biparametric</p></def></def-item><def-item><term>DCE</term><def><p id="Par13">Dynamic contrast enhanced</p></def></def-item><def-item><term>DWI</term><def><p id="Par14">Diffusion weighted imaging</p></def></def-item><def-item><term>ICC</term><def><p id="Par15">Intraclass correlation coefficient</p></def></def-item><def-item><term>mp</term><def><p id="Par16">Multiparametric</p></def></def-item><def-item><term>PCa</term><def><p id="Par17">Prostate cancer</p></def></def-item><def-item><term>PI-QUAL</term><def><p id="Par18">Prostate imaging quality scoring system</p></def></def-item><def-item><term>PI-RADS</term><def><p id="Par19">Prostate imaging reporting and data system</p></def></def-item><def-item><term>T</term><def><p id="Par20">Tesla</p></def></def-item><def-item><term>T2W</term><def><p id="Par21">T2 weighted imaging</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1186/s13244-025-01960-4.</p></sec><ack><title>Acknowledgements</title><p>We want to thank all medical centres that contributed to this manuscript by filling out the survey and/or submitting images.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>J.O.B. and M.d.R. contributed the research idea, and the methodology was designed by L.C.P.T., R.R.M.E., and M.d.R. J.J.T. created the reader study, which was performed by T.B., F.G., I.G.S., J.O.B., and M.d.R. L.C.P.T. created the survey and collected the data, assisted by R.R.M.E. Statistical analysis, writing of the original draft and editing it after review, and creation of figures were done by L.C.P.T. under the supervision of M.d.R. and M.J.M.B. J.J.T., T.B., F.G., I.G.S., R.R.M.E., M.J.M.B., J.O.B., and M.d.R. reviewed the original draft. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The authors state that this work has not received any funding.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The authors do not have permission to share the data obtained from other medical centres.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par61">Ethical approval was obtained from the Institutional Review Board. Written informed consent was waived by the Institutional Review Board. <italic>Study design:</italic> our observational retrospective study.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par62">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par63">F.G. reports consulting fees from Lucida Medical LTD and SpectraCure outside of the submitted work. The other authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2018</year><volume>68</volume><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">30207593</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394&#x02013;424<pub-id pub-id-type="pmid">30207593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">33538338</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209&#x02013;249<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics, 2012</article-title><source>CA Cancer J Clin</source><year>2015</year><volume>65</volume><fpage>87</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">25651787</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87&#x02013;108<pub-id pub-id-type="pmid">25651787</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>HU</given-names></name><name><surname>El-Shater Bosaily</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>815</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">28110982</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Ahmed HU, El-Shater Bosaily A, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815&#x02013;822<pub-id pub-id-type="pmid">28110982</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Kasivisvanathan</surname><given-names>V</given-names></name><name><surname>Rannikko</surname><given-names>AS</given-names></name><name><surname>Borghi</surname><given-names>M</given-names></name><etal/></person-group><article-title>MRI-targeted or standard biopsy for prostate-cancer diagnosis</article-title><source>N Engl J Med</source><year>2018</year><volume>378</volume><fpage>1767</fpage><lpage>1777</lpage><pub-id pub-id-type="pmid">29552975</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767&#x02013;1777<pub-id pub-id-type="pmid">29552975</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>van der Leest</surname><given-names>M</given-names></name><name><surname>Cornel</surname><given-names>E</given-names></name><name><surname>Israel</surname><given-names>B</given-names></name><etal/></person-group><article-title>Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naive men with elevated prostate-specific antigen: a large prospective multicenter clinical study</article-title><source>Eur Urol</source><year>2019</year><volume>75</volume><fpage>570</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">30477981</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">van der Leest M, Cornel E, Israel B et al (2019) Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naive men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol 75:570&#x02013;578<pub-id pub-id-type="pmid">30477981</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Wagensveld</surname><given-names>IM</given-names></name><name><surname>Osses</surname><given-names>DF</given-names></name><name><surname>Groenendijk</surname><given-names>PM</given-names></name><etal/></person-group><article-title>A prospective multicenter comparison study of risk-adapted ultrasound-directed and magnetic resonance imaging-directed diagnostic pathways for suspected prostate cancer in biopsy-naive men</article-title><source>Eur Urol</source><year>2022</year><volume>82</volume><fpage>318</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">35341658</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Wagensveld IM, Osses DF, Groenendijk PM et al (2022) A prospective multicenter comparison study of risk-adapted ultrasound-directed and magnetic resonance imaging-directed diagnostic pathways for suspected prostate cancer in biopsy-naive men. Eur Urol 82:318&#x02013;326<pub-id pub-id-type="pmid">35341658</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Mottet</surname><given-names>N</given-names></name><name><surname>van den Bergh</surname><given-names>RCN</given-names></name><name><surname>Briers</surname><given-names>E</given-names></name><etal/></person-group><article-title>EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent</article-title><source>Eur Urol</source><year>2021</year><volume>79</volume><fpage>243</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">33172724</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Mottet N, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79:243&#x02013;262<pub-id pub-id-type="pmid">33172724</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>JT</given-names></name><name><surname>Barocas</surname><given-names>D</given-names></name><name><surname>Carlsson</surname><given-names>S</given-names></name><etal/></person-group><article-title>Early detection of prostate cancer: AUA/SUO guideline part II: considerations for a prostate biopsy</article-title><source>J Urol</source><year>2023</year><volume>210</volume><fpage>54</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">37096575</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Wei JT, Barocas D, Carlsson S et al (2023) Early detection of prostate cancer: AUA/SUO guideline part II: considerations for a prostate biopsy. J Urol 210:54&#x02013;63<pub-id pub-id-type="pmid">37096575</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Gaffney</surname><given-names>CD</given-names></name><name><surname>Cai</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><etal/></person-group><article-title>Increasing utilization of MRI before prostate biopsy in black and non-black men: an analysis of the SEER-medicare cohort</article-title><source>AJR Am J Roentgenol</source><year>2021</year><volume>217</volume><fpage>389</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">34161136</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Gaffney CD, Cai P, Li D et al (2021) Increasing utilization of MRI before prostate biopsy in black and non-black men: an analysis of the SEER-medicare cohort. AJR Am J Roentgenol 217:389&#x02013;394<pub-id pub-id-type="pmid">34161136</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Patil</surname><given-names>D</given-names></name><name><surname>Howard</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Adoption of prebiopsy magnetic resonance imaging for men undergoing prostate biopsy in the United States</article-title><source>Urology</source><year>2018</year><volume>117</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">29679601</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Liu W, Patil D, Howard DH et al (2018) Adoption of prebiopsy magnetic resonance imaging for men undergoing prostate biopsy in the United States. Urology 117:57&#x02013;63<pub-id pub-id-type="pmid">29679601</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>TP</given-names></name><name><surname>Sanda</surname><given-names>MG</given-names></name><name><surname>Howard</surname><given-names>DH</given-names></name><name><surname>Patil</surname><given-names>D</given-names></name><name><surname>Filson</surname><given-names>CP</given-names></name></person-group><article-title>Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer</article-title><source>Cancer</source><year>2021</year><volume>127</volume><fpage>2974</fpage><lpage>2979</lpage><pub-id pub-id-type="pmid">34139027</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Quinn TP, Sanda MG, Howard DH, Patil D, Filson CP (2021) Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer. Cancer 127:2974&#x02013;2979<pub-id pub-id-type="pmid">34139027</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Giganti</surname><given-names>F</given-names></name><name><surname>Kirkham</surname><given-names>A</given-names></name><name><surname>Kasivisvanathan</surname><given-names>V</given-names></name><etal/></person-group><article-title>Understanding PI-QUAL for prostate MRI quality: a practical primer for radiologists</article-title><source>Insights Imaging</source><year>2021</year><volume>12</volume><fpage>59</fpage><pub-id pub-id-type="pmid">33932167</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Giganti F, Kirkham A, Kasivisvanathan V et al (2021) Understanding PI-QUAL for prostate MRI quality: a practical primer for radiologists. Insights Imaging 12:59<pub-id pub-id-type="pmid">33932167</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Giganti</surname><given-names>F</given-names></name><name><surname>Rosenkrantz</surname><given-names>AB</given-names></name><name><surname>Villeirs</surname><given-names>G</given-names></name><etal/></person-group><article-title>The Evolution of MRI of the prostate: the past, the present, and the future</article-title><source>AJR Am J Roentgenol</source><year>2019</year><volume>213</volume><fpage>384</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">31039022</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Giganti F, Rosenkrantz AB, Villeirs G et al (2019) The Evolution of MRI of the prostate: the past, the present, and the future. AJR Am J Roentgenol 213:384&#x02013;396<pub-id pub-id-type="pmid">31039022</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Westphalen</surname><given-names>AC</given-names></name><name><surname>McCulloch</surname><given-names>CE</given-names></name><name><surname>Anaokar</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Variability of the positive predictive value of PI-RADS for Prostate MRI across 26 centers: experience of the society of abdominal radiology prostate cancer disease-focused panel</article-title><source>Radiology</source><year>2020</year><volume>296</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">32315265</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Westphalen AC, McCulloch CE, Anaokar JM et al (2020) Variability of the positive predictive value of PI-RADS for Prostate MRI across 26 centers: experience of the society of abdominal radiology prostate cancer disease-focused panel. Radiology 296:76&#x02013;84<pub-id pub-id-type="pmid">32315265</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Giganti</surname><given-names>F</given-names></name><name><surname>Kasivisvanathan</surname><given-names>V</given-names></name><name><surname>Kirkham</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prostate MRI quality: a critical review of the last 5 years and the role of the PI-QUAL score</article-title><source>Br J Radiol</source><year>2022</year><volume>95</volume><fpage>20210415</fpage><pub-id pub-id-type="pmid">34233502</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Giganti F, Kasivisvanathan V, Kirkham A et al (2022) Prostate MRI quality: a critical review of the last 5 years and the role of the PI-QUAL score. Br J Radiol 95:20210415<pub-id pub-id-type="pmid">34233502</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Turkbey B, Choyke PL (2020) PI-QUAL, a new system for evaluating prostate magnetic resonance imaging quality: Is beauty in the eye of the beholder? Eur Urol Oncol. 10.1016/j.euo.2020.07.003</mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Caglic</surname><given-names>I</given-names></name><name><surname>Barrett</surname><given-names>T</given-names></name></person-group><article-title>Optimising prostate mpMRI: prepare for success</article-title><source>Clin Radiol</source><year>2019</year><volume>74</volume><fpage>831</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">30611559</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Caglic I, Barrett T (2019) Optimising prostate mpMRI: prepare for success. Clin Radiol 74:831&#x02013;840<pub-id pub-id-type="pmid">30611559</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Caglic</surname><given-names>I</given-names></name><name><surname>Hansen</surname><given-names>NL</given-names></name><name><surname>Slough</surname><given-names>RA</given-names></name><name><surname>Patterson</surname><given-names>AJ</given-names></name><name><surname>Barrett</surname><given-names>T</given-names></name></person-group><article-title>Evaluating the effect of rectal distension on prostate multiparametric MRI image quality</article-title><source>Eur J Radiol</source><year>2017</year><volume>90</volume><fpage>174</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">28583630</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Caglic I, Hansen NL, Slough RA, Patterson AJ, Barrett T (2017) Evaluating the effect of rectal distension on prostate multiparametric MRI image quality. Eur J Radiol 90:174&#x02013;180<pub-id pub-id-type="pmid">28583630</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Engels R, Israel B, Padhani AR, Barentsz JO (2019) Multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer: what urologists needs to know. Part 1: Acquisition. Eur Urol. 10.1016/j.eururo.2019.09.021</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Starobinets</surname><given-names>O</given-names></name><name><surname>Korn</surname><given-names>N</given-names></name><name><surname>Iqbal</surname><given-names>S</given-names></name><etal/></person-group><article-title>Practical aspects of prostate MRI: hardware and software considerations, protocols, and patient preparation</article-title><source>Abdom Radiol (Ny)</source><year>2016</year><volume>41</volume><fpage>817</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">27193785</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Starobinets O, Korn N, Iqbal S et al (2016) Practical aspects of prostate MRI: hardware and software considerations, protocols, and patient preparation. Abdom Radiol (Ny) 41:817&#x02013;830<pub-id pub-id-type="pmid">27193785</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Beyersdorff</surname><given-names>D</given-names></name><name><surname>Taymoorian</surname><given-names>K</given-names></name><name><surname>Knosel</surname><given-names>T</given-names></name><etal/></person-group><article-title>MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging</article-title><source>AJR Am J Roentgenol</source><year>2005</year><volume>185</volume><fpage>1214</fpage><lpage>1220</lpage><pub-id pub-id-type="pmid">16247137</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Beyersdorff D, Taymoorian K, Knosel T et al (2005) MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. AJR Am J Roentgenol 185:1214&#x02013;1220<pub-id pub-id-type="pmid">16247137</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Turkbey</surname><given-names>B</given-names></name><name><surname>Rosenkrantz</surname><given-names>AB</given-names></name><name><surname>Haider</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2</article-title><source>Eur Urol</source><year>2019</year><volume>76</volume><fpage>340</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">30898406</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76:340&#x02013;351<pub-id pub-id-type="pmid">30898406</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Burn</surname><given-names>PR</given-names></name><name><surname>Freeman</surname><given-names>SJ</given-names></name><name><surname>Andreou</surname><given-names>A</given-names></name><name><surname>Burns-Cox</surname><given-names>N</given-names></name><name><surname>Persad</surname><given-names>R</given-names></name><name><surname>Barrett</surname><given-names>T</given-names></name></person-group><article-title>A multicentre assessment of prostate MRI quality and compliance with UK and international standards</article-title><source>Clin Radiol</source><year>2019</year><volume>74</volume><fpage>894.e819</fpage><lpage>894.e825</lpage></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Burn PR, Freeman SJ, Andreou A, Burns-Cox N, Persad R, Barrett T (2019) A multicentre assessment of prostate MRI quality and compliance with UK and international standards. Clin Radiol 74:894.e819&#x02013;894.e825</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Coskun</surname><given-names>M</given-names></name><name><surname>Sarp</surname><given-names>AF</given-names></name><name><surname>Karasu</surname><given-names>S</given-names></name><name><surname>Gelal</surname><given-names>MF</given-names></name></person-group><article-title>Assessment of the compliance with minimum acceptable technical parameters proposed by PI-RADS v2 guidelines in multiparametric prostate MRI acquisition in tertiary referral hospitals in the Republic of Turkey</article-title><source>Diagn Interv Radiol</source><year>2019</year><volume>25</volume><fpage>421</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">31650967</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Coskun M, Sarp AF, Karasu S, Gelal MF (2019) Assessment of the compliance with minimum acceptable technical parameters proposed by PI-RADS v2 guidelines in multiparametric prostate MRI acquisition in tertiary referral hospitals in the Republic of Turkey. Diagn Interv Radiol 25:421&#x02013;427<pub-id pub-id-type="pmid">31650967</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Cuocolo</surname><given-names>R</given-names></name><name><surname>Stanzione</surname><given-names>A</given-names></name><name><surname>Ponsiglione</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prostate MRI technical parameters standardization: a systematic review on adherence to PI-RADSv2 acquisition protocol</article-title><source>Eur J Radiol</source><year>2019</year><volume>120</volume><fpage>108662</fpage><pub-id pub-id-type="pmid">31539790</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Cuocolo R, Stanzione A, Ponsiglione A et al (2019) Prostate MRI technical parameters standardization: a systematic review on adherence to PI-RADSv2 acquisition protocol. Eur J Radiol 120:108662<pub-id pub-id-type="pmid">31539790</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Esses</surname><given-names>SJ</given-names></name><name><surname>Taneja</surname><given-names>SS</given-names></name><name><surname>Rosenkrantz</surname><given-names>AB</given-names></name></person-group><article-title>Imaging facilities&#x02019; adherence to PI-RADS v2 minimum technical standards for the performance of prostate MRI</article-title><source>Acad Radiol</source><year>2018</year><volume>25</volume><fpage>188</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">29107458</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Esses SJ, Taneja SS, Rosenkrantz AB (2018) Imaging facilities&#x02019; adherence to PI-RADS v2 minimum technical standards for the performance of prostate MRI. Acad Radiol 25:188&#x02013;195<pub-id pub-id-type="pmid">29107458</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Leake</surname><given-names>JL</given-names></name><name><surname>Hardman</surname><given-names>R</given-names></name><name><surname>Ojili</surname><given-names>V</given-names></name><etal/></person-group><article-title>Prostate MRI: access to and current practice of prostate MRI in the United States</article-title><source>J Am Coll Radiol</source><year>2014</year><volume>11</volume><fpage>156</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">24389134</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Leake JL, Hardman R, Ojili V et al (2014) Prostate MRI: access to and current practice of prostate MRI in the United States. J Am Coll Radiol 11:156&#x02013;160<pub-id pub-id-type="pmid">24389134</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Sackett J, Shih JH, Reese SE et al (2020) Quality of prostate MRI: Is the PI-RADS standard sufficient? Acad Radiol. 10.1016/j.acra.2020.01.031</mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>de Rooij</surname><given-names>M</given-names></name><name><surname>Israel</surname><given-names>B</given-names></name><name><surname>Tummers</surname><given-names>M</given-names></name><etal/></person-group><article-title>ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists&#x02019; training</article-title><source>Eur Radiol</source><year>2020</year><volume>30</volume><fpage>5404</fpage><lpage>5416</lpage><pub-id pub-id-type="pmid">32424596</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">de Rooij M, Israel B, Tummers M et al (2020) ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists&#x02019; training. Eur Radiol 30:5404&#x02013;5416<pub-id pub-id-type="pmid">32424596</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">de Rooij M, Allen C, Twilt JJ et al (2024) PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI. Eur Radiol. 10.1007/s00330-024-10795-4</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Weinreb</surname><given-names>JC</given-names></name><name><surname>Barentsz</surname><given-names>JO</given-names></name><name><surname>Choyke</surname><given-names>PL</given-names></name><etal/></person-group><article-title>PI-RADS prostate imaging&#x02014;reporting and data system: 2015, version 2</article-title><source>Eur Urol</source><year>2016</year><volume>69</volume><fpage>16</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">26427566</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Weinreb JC, Barentsz JO, Choyke PL et al (2016) PI-RADS prostate imaging&#x02014;reporting and data system: 2015, version 2. Eur Urol 69:16&#x02013;40<pub-id pub-id-type="pmid">26427566</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Barentsz</surname><given-names>JO</given-names></name><name><surname>Richenberg</surname><given-names>J</given-names></name><name><surname>Clements</surname><given-names>R</given-names></name><etal/></person-group><article-title>ESUR prostate MR guidelines 2012</article-title><source>Eur Radiol</source><year>2012</year><volume>22</volume><fpage>746</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">22322308</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Barentsz JO, Richenberg J, Clements R et al (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22:746&#x02013;757<pub-id pub-id-type="pmid">22322308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Giganti</surname><given-names>F</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><name><surname>Asif</surname><given-names>A</given-names></name><etal/></person-group><article-title>Global variation in magnetic resonance imaging quality of the prostate</article-title><source>Radiology</source><year>2023</year><volume>309</volume><fpage>e231130</fpage><pub-id pub-id-type="pmid">37815448</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Giganti F, Ng A, Asif A et al (2023) Global variation in magnetic resonance imaging quality of the prostate. Radiology 309:e231130<pub-id pub-id-type="pmid">37815448</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Papoutsaki</surname><given-names>MV</given-names></name><name><surname>Allen</surname><given-names>C</given-names></name><name><surname>Giganti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Standardisation of prostate multiparametric MRI across a hospital network: a London experience</article-title><source>Insights Imaging</source><year>2021</year><volume>12</volume><fpage>52</fpage><pub-id pub-id-type="pmid">33877459</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Papoutsaki MV, Allen C, Giganti F et al (2021) Standardisation of prostate multiparametric MRI across a hospital network: a London experience. Insights Imaging 12:52<pub-id pub-id-type="pmid">33877459</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Gatti</surname><given-names>M</given-names></name><name><surname>Faletti</surname><given-names>R</given-names></name><name><surname>Calleris</surname><given-names>G</given-names></name><etal/></person-group><article-title>Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI)</article-title><source>Abdom Radiol (Ny)</source><year>2019</year><volume>44</volume><fpage>1883</fpage><lpage>1893</lpage><pub-id pub-id-type="pmid">30788558</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Gatti M, Faletti R, Calleris G et al (2019) Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). Abdom Radiol (Ny) 44:1883&#x02013;1893<pub-id pub-id-type="pmid">30788558</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Belue MJ, Yilmaz EC, Daryanani A, Turkbey B (2022) Current status of biparametric MRI in prostate cancer diagnosis: literature analysis. Life 12:804</mixed-citation></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Schoots</surname><given-names>IG</given-names></name><name><surname>Barentsz</surname><given-names>JO</given-names></name><name><surname>Bittencourt</surname><given-names>LK</given-names></name><etal/></person-group><article-title>PI-RADS committee position on MRI without contrast medium in biopsy-naive men with suspected prostate cancer: narrative review</article-title><source>AJR Am J Roentgenol</source><year>2021</year><volume>216</volume><fpage>3</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">32812795</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Schoots IG, Barentsz JO, Bittencourt LK et al (2021) PI-RADS committee position on MRI without contrast medium in biopsy-naive men with suspected prostate cancer: narrative review. AJR Am J Roentgenol 216:3&#x02013;19<pub-id pub-id-type="pmid">32812795</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Palumbo</surname><given-names>P</given-names></name><name><surname>Manetta</surname><given-names>R</given-names></name><name><surname>Izzo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Biparametric (bp) and multiparametric (mp) magnetic resonance imaging (MRI) approach to prostate cancer disease: a narrative review of current debate on dynamic contrast enhancement</article-title><source>Gland Surg</source><year>2020</year><volume>9</volume><fpage>2235</fpage><lpage>2247</lpage><pub-id pub-id-type="pmid">33447576</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Palumbo P, Manetta R, Izzo A et al (2020) Biparametric (bp) and multiparametric (mp) magnetic resonance imaging (MRI) approach to prostate cancer disease: a narrative review of current debate on dynamic contrast enhancement. Gland Surg 9:2235&#x02013;2247<pub-id pub-id-type="pmid">33447576</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Schick</surname><given-names>F</given-names></name></person-group><article-title>Whole-body MRI at high field: technical limits and clinical potential</article-title><source>Eur Radiol</source><year>2005</year><volume>15</volume><fpage>946</fpage><lpage>959</lpage><pub-id pub-id-type="pmid">15856252</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Schick F (2005) Whole-body MRI at high field: technical limits and clinical potential. Eur Radiol 15:946&#x02013;959<pub-id pub-id-type="pmid">15856252</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Ullrich</surname><given-names>T</given-names></name><name><surname>Quentin</surname><given-names>M</given-names></name><name><surname>Oelers</surname><given-names>C</given-names></name><etal/></person-group><article-title>Magnetic resonance imaging of the prostate at 1.5 versus 3.0T: a prospective comparison study of image quality</article-title><source>Eur J Radiol</source><year>2017</year><volume>90</volume><fpage>192</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">28583633</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Ullrich T, Quentin M, Oelers C et al (2017) Magnetic resonance imaging of the prostate at 1.5 versus 3.0T: a prospective comparison study of image quality. Eur J Radiol 90:192&#x02013;197<pub-id pub-id-type="pmid">28583633</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>DL</given-names></name><name><surname>Lazarakis</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>TH</given-names></name><name><surname>Chin</surname><given-names>KY</given-names></name><name><surname>Oon</surname><given-names>SF</given-names></name></person-group><article-title>Do antispasmodics or rectal enemas improve image quality on multiparametric prostate MRI? An &#x02018;Evidence-Based Practice&#x02019; review of the literature</article-title><source>Abdom Radiol (Ny)</source><year>2021</year><volume>46</volume><fpage>2770</fpage><lpage>2778</lpage><pub-id pub-id-type="pmid">33464364</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Brennan DL, Lazarakis S, Lee A, Tan TH, Chin KY, Oon SF (2021) Do antispasmodics or rectal enemas improve image quality on multiparametric prostate MRI? An &#x02018;Evidence-Based Practice&#x02019; review of the literature. Abdom Radiol (Ny) 46:2770&#x02013;2778<pub-id pub-id-type="pmid">33464364</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Slough</surname><given-names>RA</given-names></name><name><surname>Caglic</surname><given-names>I</given-names></name><name><surname>Hansen</surname><given-names>NL</given-names></name><name><surname>Patterson</surname><given-names>AJ</given-names></name><name><surname>Barrett</surname><given-names>T</given-names></name></person-group><article-title>Effect of hyoscine butylbromide on prostate multiparametric MRI anatomical and functional image quality</article-title><source>Clin Radiol</source><year>2018</year><volume>73</volume><fpage>216.e219</fpage><lpage>216.e214</lpage></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Slough RA, Caglic I, Hansen NL, Patterson AJ, Barrett T (2018) Effect of hyoscine butylbromide on prostate multiparametric MRI anatomical and functional image quality. Clin Radiol 73:216.e219&#x02013;216.e214</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>T</given-names></name><name><surname>Padhani</surname><given-names>AR</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><etal/></person-group><article-title>Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting</article-title><source>BJU Int</source><year>2021</year><volume>127</volume><fpage>304</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">33113258</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Barrett T, Padhani AR, Patel A et al (2021) Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting. BJU Int 127:304&#x02013;306<pub-id pub-id-type="pmid">33113258</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>T</given-names></name><name><surname>Ghafoor</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Prostate MRI qualification: AJR expert panel narrative review</article-title><source>AJR Am J Roentgenol</source><year>2022</year><volume>219</volume><fpage>691</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">35544372</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Barrett T, Ghafoor S, Gupta RT et al (2022) Prostate MRI qualification: AJR expert panel narrative review. AJR Am J Roentgenol 219:691&#x02013;702<pub-id pub-id-type="pmid">35544372</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Giganti</surname><given-names>F</given-names></name><name><surname>Allen</surname><given-names>C</given-names></name><name><surname>Emberton</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>CM</given-names></name><name><surname>Kasivisvanathan</surname><given-names>V</given-names></name><collab>group Ps</collab></person-group><article-title>Prostate imaging quality (PI-QUAL): a new quality control scoring system for multiparametric magnetic resonance imaging of the prostate from the PRECISION trial</article-title><source>Eur Urol Oncol</source><year>2020</year><volume>3</volume><fpage>615</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">32646850</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Giganti F, Allen C, Emberton M, Moore CM, Kasivisvanathan V, group Ps (2020) Prostate imaging quality (PI-QUAL): a new quality control scoring system for multiparametric magnetic resonance imaging of the prostate from the PRECISION trial. Eur Urol Oncol 3:615&#x02013;619<pub-id pub-id-type="pmid">32646850</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Giganti</surname><given-names>F</given-names></name><name><surname>Cole</surname><given-names>AP</given-names></name><name><surname>Fennessy</surname><given-names>FM</given-names></name><etal/></person-group><article-title>Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship</article-title><source>Eur Radiol</source><year>2023</year><volume>33</volume><fpage>461</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">35771247</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Giganti F, Cole AP, Fennessy FM et al (2023) Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship. Eur Radiol 33:461&#x02013;471<pub-id pub-id-type="pmid">35771247</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Pinto</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effect of a dedicated PI-QUAL curriculum on the assessment of prostate MRI quality</article-title><source>Eur J Radiol</source><year>2023</year><volume>164</volume><fpage>110865</fpage><pub-id pub-id-type="pmid">37167684</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Wang R, Pinto D, Liu T et al (2023) Effect of a dedicated PI-QUAL curriculum on the assessment of prostate MRI quality. Eur J Radiol 164:110865<pub-id pub-id-type="pmid">37167684</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>